MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 01-14-2026
Biomerica Retained Earnings 2011-2026 | BMRA
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Biomerica
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -53.2 M | -48.2 M | -42.2 M | -35.1 M | -30.5 M | -21.9 M | -19.6 M | -17.2 M | -15.7 M | -14.8 M | -13.3 M | -13 M | -12.8 M | -13.3 M | -13.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -12.8 M | -53.2 M | -24.3 M |
Quarterly Retained Earnings Biomerica
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -54.5 M | -53.2 M | -53.2 M | -51.6 M | -50.5 M | -49.5 M | -48.2 M | -46.8 M | -44.9 M | -43.3 M | -42.2 M | -40.4 M | -38.8 M | -37.1 M | -35.1 M | -33.3 M | -33.2 M | -32.1 M | -30.5 M | -30.5 M | -25.1 M | -23.6 M | -23.1 M | -21.9 M | -20.6 M | -20.1 M | -19.6 M | -19.6 M | -18.1 M | -17.6 M | -17.2 M | -17.2 M | -16.2 M | -15.9 M | -15.7 M | -15.7 M | -15.1 M | -14.9 M | -14.8 M | -14.8 M | -13.5 M | -13.4 M | -13.3 M | -13.3 M | -13.4 M | -13.2 M | -13 M | -13 M | -13.2 M | -12.9 M | -12.8 M | -12.8 M | -12.8 M | -13 M | -13.3 M | -13.3 M | -13.5 M | -13.7 M | -13.9 M | -13.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -12.8 M | -54.5 M | -24.7 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Anixa Biosciences
ANIX
|
-252 M | $ 3.03 | -2.26 % | $ 98.3 K |  USA |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-499 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Brainsway Ltd.
BWAY
|
-77.3 M | $ 23.35 | -2.91 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 34.5 | 2.16 % | $ 371 M |  China |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
BioNano Genomics
BNGO
|
-693 M | $ 1.29 | -12.26 % | $ 1.64 M | USA |
 |
Castle Biosciences
CSTL
|
-200 M | $ 39.74 | 1.48 % | $ 1.1 B | USA |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M | Israel |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
4.6 M | - | - | $ 79.8 M | USA |
 |
Danaher Corporation
DHR
|
44.2 B | $ 219.29 | -0.08 % | $ 160 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.5 B | $ 102.41 | 0.1 % | $ 19 B | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 26.19 | -0.19 % | $ 792 M | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Guardant Health
GH
|
-2.58 B | $ 113.17 | 2.43 % | $ 13.9 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
DexCom
DXCM
|
1.02 B | $ 73.31 | -0.93 % | $ 28.3 B | USA |
 |
CareDx, Inc
CDNA
|
-678 M | $ 20.55 | -1.23 % | $ 1.1 B | USA |
 |
Celcuity
CELC
|
-272 M | $ 109.48 | -2.35 % | $ 4.32 B | USA |
 |
DarioHealth Corp.
DRIO
|
-349 M | $ 10.2 | -0.97 % | $ 289 M | Israel |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
446 M | $ 66.91 | 0.34 % | $ 4.63 B | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 144.81 | -3.26 % | $ 23 B | USA |
 |
NeoGenomics
NEO
|
-326 M | $ 11.99 | -3.35 % | $ 1.52 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.45 B | - | - | $ 10.6 B |  Niderland |
 |
IQVIA Holdings
IQV
|
6.06 B | $ 230.33 | -2.19 % | $ 41.8 B | USA |
 |
Charles River Laboratories International
CRL
|
1.81 B | $ 210.51 | -0.59 % | $ 10.8 B | USA |
 |
Personalis
PSNL
|
-550 M | $ 9.33 | -6.42 % | $ 553 M | USA |
 |
Medpace Holdings
MEDP
|
8.17 M | $ 582.66 | -1.76 % | $ 18 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.36 B | $ 186.45 | 2.27 % | $ 20.7 B | USA |
|
Biodesix
BDSX
|
-462 M | $ 10.11 | 4.66 % | $ 1.31 B | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Precipio
PRPO
|
-98.2 M | $ 24.07 | -0.78 % | $ 31.2 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.3 B | $ 271.34 | 0.56 % | $ 22.8 B | USA |
 |
Mettler-Toledo International
MTD
|
8.37 B | $ 1 370.47 | -1.61 % | $ 29.1 B |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 181.44 | -2.39 % | $ 15 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
5.33 B | $ 672.84 | -0.57 % | $ 55.5 B | USA |
 |
Agilent Technologies
A
|
348 M | $ 133.33 | 0.07 % | $ 40.5 B | USA |